E85
Conditions
Interventions
Group 1: Observational group of data which are assesed in clinical routine in the context of ATTR amyloidosis in the treating center. This comprises comorbidity and histotry of amyloidosis symptoms an
Sponsors
Klinik III für Innere Medizin, Herzzentrum, Universitätsklinik Köln
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosis of transthyretin amyloidosis or transthyretin gene variant carrier
Exclusion criteria
Exclusion criteria: lack of informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aim of the study is to assess parameters indicating disease severity of ATTR cardiomyopathy from the domains: clinical (mortality, hospitalization, functionality), imaging and ECG, biomarker These are assessed from clinical routine on a yearly basis at the treating center. | — |
Secondary
| Measure | Time frame |
|---|---|
| - parameters indicating extracardiac severity of disease (neurology) - disease specific and supportive treatments - development of manifest amyloidosis in transthyretin gene carriers - development of cardiac amyloidosis in patients with extracardiac amyloidosis manifestation | — |
Countries
Germany
Contacts
Public ContactRoman Pfister
Klinik III für Innere Medizin, Herzzentrum, Universitätsklinik Köln
Outcome results
None listed